US Acute Coronary Syndrome Drugs Industry (Antithrombotics, Antihypertensives & Statins) and Market Analysis to 2023

DALLAS, September 7, 2014 /PRNewswire/ --

MarketOptimizer.org adds "Acute Coronary Syndrome - US Drug Forecast and Market Analysis to 2023", a new research report to its store. Overview of ACS, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

The Acute Coronary Syndrome - US Drug Forecast and Market Analysis to 2023 report estimates that the total market size for the 7MM in 2013 was $12.3bn, comprised of $5.0bn in branded drug sales (40%) and $7.3bn in generic sales (60%). It expects that the ACS drug market will grow at a CAGR of 13.4% over the ten year forecast period, resulting in a market value of $43.4bn by 2023, of which 64% will be attributed to branded drug sales ($27.7bn) and 36% to generic drug sales ($15.7bn). The current Acute Coronary Syndrome market - primarily comprised of antithrombotics, antihypertensives, and statins - is flush with well-established standard-of-care therapies, many of which are generic. Therefore, the pipeline therapies that show the most promise exploit novel mechanisms of action and target orphan biochemical pathways. The ACS market will be driven by an aging population with a preponderance of lifestyle-based diseases, such as obesity, and the growing prevalence of metabolic disorders such as diabetes. The expansion of biologics into the ACS mainstream during the ten year forecast period is expected to significantly and fundamentally alter the ACS market, both medically and financially.

Of the 7MM forecast for acute coronary syndrome, the US market dominates the other six countries in sales for every class and brand of drug, by a very large margin. The statin share can predominantly be attributed to sales volume as most statins, with the exception of Crestor, are available as inexpensive generics. Contrarily, the large market share from the ARBs is due to the relatively high cost of therapy and the presence of branded options still on the market.

Order a Copy of Acute Coronary Syndrome - US Drug Forecast and Market Analysis to 2023 research report @ http://www.marketoptimizer.org/contacts/purchase?rname=10327 .

Overview of Product Profile in US Acute Coronary Syndrome Industry:

• Fibrinolytic (Thrombolytic) Drugs - Tissue Plasminogen Activator (tPA)
• Clopidogrel
• Brilinta (ticagrelor)
• Effient (prasugrel)
• Integrilin (eptifibatide)
• Warfarin
• Angiomax (bivalirudin)
• Arixtra (fondaparinux) and the Heparins
• Statins - HMG-CoA Reductase Inhibitors
• Beta-Adrenergic Receptor Antagonists (Beta Blockers)
• Renin-Angiotensin-Aldosterone System (RAAS) Inhibitors

Scope of this report covers: Overview of ACS including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape; Detailed information on the key drugs in the US including product description, safety and efficacy profiles as well as a SWOT analysis; Sales forecast for the top drugs in the US from 2013-2023 and Analysis of the impact of key events as well the drivers and restraints affecting the US ACS market.

Reasons to Buy 

• Understand and capitalize by identifying products that are most likely to ensure a robust return
• Stay ahead of the competition by understanding the changing competitive landscape for ACS
• Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
• Make more informed business decisions from insightful and in-depth analysis of drug performance
• Obtain sales forecast for drugs from 2013-2023 in the US

Major Points in Table of Contents of Acute Coronary Syndrome - US Drug Forecast and Market Analysis to 2023 Research Report: 

2 Esecutive Summary 

3 Introduction 

4 Disease Overview 

5 Disease Management 

6 Competitive Assessment 

7 Unmet Need and Opportunity
7.1 Overview
7.2 Therapies that Directly Treat Thrombogenic Atherosclerotic Plaques
7.2.1 Unmet Need
7.2.2 Gap Analysis
7.2.3 Opportunity
7.3 Therapies that Treat Fibrotic Myocardium and Associated Comorbidities
7.4 LDL-C-Lowering Drugs for Statin-Intolerant, Refractory, or Non-Compliant Patients
7.5 Antidotes for New Oral Anticoagulants (NOACs)
7.6 Blood-Thinning Agents with Significantly Reduced Bleeding Risks

Inquiry before Buying @ http://www.marketoptimizer.org/contacts/inquire-before-buying?rname=10327 . (This is a premium report priced at US$6995 for a single user License.)

8 Pipeline Assessment
8.1 Overview
8.2 Clinical Trials by Phase and Trial Status
8.3 Promising Drugs in Clinical Development
8.3.1 Xarelto (rivaroxaban)
8.3.2 Cangrelor
8.3.3 Zontivity (vorapaxar)
8.3.4 Alirocumab (RGN727)
8.3.5 Evolocumab (AMG 145)
8.3.6 Bococizumab (PF-04950615)
8.3.7 Anacetrapib
8.3.8 Evacetrapib
8.3.9 Darapladib

List of Tables
Table 1: Antiplatelet Agents that Inhibit Platelet Activation
Table 2: Anticoagulants that Inhibit the Coagulatory Cascade
Table 3: Symptoms of Acute Coronary Syndrome
Table 4: Treatment Guidelines for Acute Coronary Syndromes (UA, NSTEMI, and STEMI)
Table 5: Most Prescribed Drugs for ACS by Class in the US, 2014
Table 6: Leading Treatments for Acute Coronary Syndrome, 2014
Table 7: Commonly Used tPAs
Table 8: Product Profile - Tissue Plasminogen Activator (tPA)
Table 9: Fibrinolytics?SWOT Analysis, 2014
Table 10: Product Profile - Plavix (clopidogrel)
Table 11: Clopidogrel SWOT Analysis, 2014
Table 12: Product Profile - Brilinta (ticagrelor)
Table 13: Brilinta (ticagrelor) SWOT Analysis, 2014
Table 14: Product Profile - Effient (prasugrel)
Table 15: Effient (prasugrel) SWOT Analysis, 2014
Table 16: Product Profile - Integrilin (eptifibatide)
Table 17: Integrilin (eptifibatide) SWOT Analysis, 2014
Table 18: Product Profile - Warfarin
Table 19: Warfarin SWOT Analysis, 2014
Table 20: Product Profile - Angiomax
Table 21: Angiomax (bivalirudin) SWOT Analysis, 2014
Table 22: Product Profile - Arixtra (fondaparinux)
Table 23: Arixtra (fondaparinux sodium) SWOT Analysis, 2014
Table 24: Product Profile - Lipitor
Table 25: Lipitor (atorvastatin) SWOT Analysis, 2014
Table 26: Product Profile - Crestor (rosuvastatin)
Table 27: Crestor (rosuvastatin) SWOT Analysis, 2014
Table 28: Product Profile - Zocor (simvastatin)
Table 29: Zocor (simvastatin) SWOT Analysis, 2014
Table 30: Commonly Used Beta Blockers
Table 31: Product Profile - Beta Blockers
Table 32: Beta Blockers SWOT Analysis, 2014
Table 33: Product Profile - Tekturna (aliskiren)
Table 34: Tekturna (aliskiren) SWOT Analysis, 2014
Table 35: Commonly Used ACE Inhibitors
Table 36: Product Profile - ACE Inhibitors
Table 37: ACE Inhibitor?SWOT Analysis, 2014
Table 38: Commonly Used ARBs
Table 39: Product Profile - Angiotensin Receptor Blockers (ARBs)
Table 40: ARB SWOT Analysis, 2014

Explore more reports on Pharmaceuticals industry at http://www.marketoptimizer.org/category/life-sciences/pharmaceuticals .

About Us:

MarketOptimizer.org is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.

Contact:
Ritesh Tiwari
TX, Dallas North - Dominion Plaza
17304, Preston Road,
Suite 800, Dallas 75252
Tel: +1-888-391-5441
[email protected]

SOURCE Market Optimizer